Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ESMO 2014

Promoting connectivity and exchange between young cancer researchers and clinicians: ESMO young oncologists meet the EACR

Promoting connectivity and exchange between young cancer researchers and clinicians: ESMO young oncologists meet...

Personalised medicine, cancer spectrum and the immunome: ESMO 2014 highlights frontiers of cancer care

Personalised medicine, cancer spectrum and the immunome: ESMO 2014 highlights frontiers of cancer care

Intralesional injections show promise for cutaneous melanoma

Intralesional injections show promise for cutaneous melanoma

ESMO 2014: PIK3CA mutations blunt benefit of anti-HER2 drugs in breast cancer

ESMO 2014: PIK3CA mutations blunt benefit of anti-HER2 drugs in breast cancer

ESMO 2014: Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

ESMO 2014: Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

ESMO 2014: HER2 inhibition shows promise in HER2-positive non-small cell lung cancer

ESMO 2014: HER2 inhibition shows promise in HER2-positive non-small cell lung cancer

ESMO 2014: Dabrafenib anti-tumour activity in BRAF V600E mutation-positive non-small cell lung cancer

ESMO 2014: Dabrafenib anti-tumour activity in BRAF V600E mutation-positive non-small cell lung cancer

ESMO 2014: PD-L1 protein a possible immunotherapy target in mesothelioma

ESMO 2014: PD-L1 protein a possible immunotherapy target in mesothelioma

ESMO 2014: High-dose radiotherapy adds no survival benefit after chemotherapy and radical surgery in mesothelioma

ESMO 2014: High-dose radiotherapy adds no survival benefit after chemotherapy and radical surgery in mesothelioma

ESMO 2014: Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

ESMO 2014: Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

ESMO 2014: Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

ESMO 2014: Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

ESMO 2014: Phase III trial results raise questions about the future of lung cancer vaccination

ESMO 2014: Phase III trial results raise questions about the future of lung cancer vaccination

ESMO 2014: Many patients lack information about the use of targeted therapies, oncologists say

ESMO 2014: Many patients lack information about the use of targeted therapies, oncologists say

ESMO 2014: Significant presence of women in oncology but still under-representation in leadership positions, Greek survey shows

ESMO 2014: Significant presence of women in oncology but still under-representation in leadership positions, Greek...

ESMO 2014: Little benefit for gefitinib-resistant lung cancer when continuing the drug with chemo

ESMO 2014: Little benefit for gefitinib-resistant lung cancer when continuing the drug with chemo

ESMO 2014: Adding cediranib to chemo improves PFS for metastatic cervical cancer

ESMO 2014: Adding cediranib to chemo improves PFS for metastatic cervical cancer

ESMO 2014: Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

ESMO 2014: Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive...

ESMO 2014: Docetaxel or pemetrexed in addition to cisplatin achieve comparable outcomes in non-squamous lung cancer

ESMO 2014: Docetaxel or pemetrexed in addition to cisplatin achieve comparable outcomes in non-squamous lung cancer

ESMO 2014: Faecal occult blood screening in colorectal cancer increases high-risk polyp detection by 89%

ESMO 2014: Faecal occult blood screening in colorectal cancer increases high-risk polyp detection by 89%

ESMO 2014: Scan may identify lung cancer patients who will benefit from folate-targeted drug

ESMO 2014: Scan may identify lung cancer patients who will benefit from folate-targeted drug

ESMO 2014: Thymidylate synthase as a predictive and prospective biomarker in lung cancer

ESMO 2014: Thymidylate synthase as a predictive and prospective biomarker in lung cancer

ESMO 2014: Colonoscopy less effective than faecal occult blood tests in patients at high risk of colorectal cancer

ESMO 2014: Colonoscopy less effective than faecal occult blood tests in patients at high risk of colorectal cancer

ESMO 2014: Rolapitant reduces nausea and vomiting associated with cisplatin-based chemotherapy

ESMO 2014: Rolapitant reduces nausea and vomiting associated with cisplatin-based chemotherapy

ESMO 2014: Anamorelin improves appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia

ESMO 2014: Anamorelin improves appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia

ESMO 2014: Second-line afatinib significantly improves PFS in metastatic head and neck cancer

ESMO 2014: Second-line afatinib significantly improves PFS in metastatic head and neck cancer

ESMO 2014: Discussions about contraception important following cancer diagnosis

ESMO 2014: Discussions about contraception important following cancer diagnosis

ESMO 2014: Sentinel node biopsy safe for pregnant women with cancer

ESMO 2014: Sentinel node biopsy safe for pregnant women with cancer

ESMO 2014: Study shows chemotherapy and radiotherapy are safe for babies in utero

ESMO 2014: Study shows chemotherapy and radiotherapy are safe for babies in utero

ESMO 2014: Access to breast cancer drug lacking in Eastern Europe

ESMO 2014: Access to breast cancer drug lacking in Eastern Europe

ESMO 2014: Canada and Europe sometimes years slower than USA in approving cancer drugs

ESMO 2014: Canada and Europe sometimes years slower than USA in approving cancer drugs

ESMO 2014: More than 70% of young oncologists in Europe suffer symptoms of burnout

ESMO 2014: More than 70% of young oncologists in Europe suffer symptoms of burnout

EAPM takes its messages to the European Society Medical Oncology Congress

EAPM takes its messages to the European Society Medical Oncology Congress

Healthcare professionals reunite at ESMO 2014 to support multidisciplinary care for head and neck cancer patients across Europe

Healthcare professionals reunite at ESMO 2014 to support multidisciplinary care for head and neck cancer patients...

Fifteen new designated centres of integrated oncology and palliative care announced

Fifteen new designated centres of integrated oncology and palliative care announced

ESMO announces Hamilton Fairley Award recipient as Heikki Joensuu

ESMO announces Hamilton Fairley Award recipient as Heikki Joensuu

ESMO Lifetime Achievement Award recognises Peter Boyle

ESMO Lifetime Achievement Award recognises Peter Boyle

ESMO Award goes to Carsten Bokemeyer

ESMO Award goes to Carsten Bokemeyer

More from ecancer